Heng Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Heng Lu has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Yiqi Zhang
The First Affiliated Hospital of Jinzhou Medical University, Jinzhou City, Liaoning Province, 110001, PR China
3 shared publications- Ang Zheng
Department of Breast Surgery, The First Hospital of China Medical University
2 shared publications Yinlin Li
The First Affiliated Hospital of Jinzhou Medical University, Jinzhou City, Liaoning Province, 110001, PR China
2 shared publicationsAng Zheng
The First Affiliated Hospital of China Medical University
1 shared publicationChunyu Wang
Department of Cell Biology, Key Laboratory of Cell Biology, National Health Commission, and Key Laboratory of Medical Cell Biology, Ministry of Education, School of Life Sciences, China Medical University, Shenyang, People’s Republic of China
1 shared publicationFeng Jin
Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, People’s Republic of China
1 shared publication
Latest Publications
- Open Access
- 29 October 2025
- Published by Springer Nature in Cell & Bioscience
- Vol. 15 (1) , 1-15
BAP18, as a corepressor of AR together with the SIN3A/HDAC complex, promotes AR-positive triple-negative breast cancer progression
Triple-negative breast cancer (TNBC) is considered a highly heterogeneous disease. Androgen receptor (AR)-positive TNBC is a subtype with distinct molecular features. However, the molecular mechanism underlying the modulation of the AR signaling pathway in TNBC is still elusive. BPTF-associated protein of 18 kDa (BAP18) was significantly upregulated in AR-positive TNBC samples and was positively correlated with advanced disease stage and poor prognosis. BAP18 was shown to act as a transcriptional corepressor of AR in AR-positive TNBC cells and is involved in the promotion of AR-positive TNBC. Mechanically, BAP18 associates with AR and the SIN3A/HDAC subcomplex. BAP18 facilitates the recruitment of SIN3A/HDAC to androgen response elements (AREs) in the promoter regions of P21 and PTEN, subsequently leading to a reduced level of histone H4 acetylation on AREs. Our study revealed that BAP18, which acts as a novel AR corepressor, is involved in AR-positive TNBC progression, suggesting that BAP18 could be a potential therapeutic target for AR-positive TNBC patients.
- 29 October 2025
- Published by Springer Nature in Cell & Bioscience
- Vol. 15 (1) , 1-15
Open AccessBAP18, as a corepressor of AR together with the SIN3A/HDAC complex, promotes AR-positive triple-negative breast cancer progression
Triple-negative breast cancer (TNBC) is considered a highly heterogeneous disease. Androgen receptor (AR)-positive TNBC is a subtype with distinct molecular features. However, the molecular mechanism underlying the modulation of the AR signaling pathway in TNBC is still elusive. BPTF-associated protein of 18 kDa (BAP18) was significantly upregulated in AR-positive TNBC samples and was positively correlated with advanced disease stage and poor prognosis. BAP18 was shown to act as a transcriptional corepressor of AR in AR-positive TNBC cells and is involved in the promotion of AR-positive TNBC. Mechanically, BAP18 associates with AR and the SIN3A/HDAC subcomplex. BAP18 facilitates the recruitment of SIN3A/HDAC to androgen response elements (AREs) in the promoter regions of P21 and PTEN, subsequently leading to a reduced level of histone H4 acetylation on AREs. Our study revealed that BAP18, which acts as a novel AR corepressor, is involved in AR-positive TNBC progression, suggesting that BAP18 could be a potential therapeutic target for AR-positive TNBC patients.
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 57, e13809
SNORA5A regulates tumor-associated macrophage M1/M2 phenotypes via TRAF3IP3 in breast cancer
Small nucleolar RNAs (snoRNAs) have robust potential functions and therapeutic value in breast cancer. Herein, we investigated the role SNORA5A in breast cancer. Samples from The Cancer Genome Atlas (TCGA) were reviewed. The transcription matrix and clinical information were analyzed using R software and validated in clinical tissue samples. SNORA5A was significantly down-regulated in breast cancer, and high expression of SNORA5A correlated with a favorable prognosis. High expression of SNORA5A induced a high concentration of tumor-associated macrophages M1 and a low concentration of tumor-associated macrophages M2. Moreover, SNORA5A were clustered in terms related to cancer and immune functions. Possible downstream molecules of SNORA5A were identified, among which TRAF3IP3 was positively correlated with M1 and negatively correlated with M2. The function of TRAF3IP3 in tumor inhibition and its relationship with macrophages in clinical tissue samples were in accordance with bioinformatics analysis results. SNORA5A could regulate macrophage phenotypes through TRAF3IP3 and serves as a potential prognostic marker for breast cancer patients.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Medical and Biological Research
- Vol. 57, e13809
Open AccessSNORA5A regulates tumor-associated macrophage M1/M2 phenotypes via TRAF3IP3 in breast cancer
Small nucleolar RNAs (snoRNAs) have robust potential functions and therapeutic value in breast cancer. Herein, we investigated the role SNORA5A in breast cancer. Samples from The Cancer Genome Atlas (TCGA) were reviewed. The transcription matrix and clinical information were analyzed using R software and validated in clinical tissue samples. SNORA5A was significantly down-regulated in breast cancer, and high expression of SNORA5A correlated with a favorable prognosis. High expression of SNORA5A induced a high concentration of tumor-associated macrophages M1 and a low concentration of tumor-associated macrophages M2. Moreover, SNORA5A were clustered in terms related to cancer and immune functions. Possible downstream molecules of SNORA5A were identified, among which TRAF3IP3 was positively correlated with M1 and negatively correlated with M2. The function of TRAF3IP3 in tumor inhibition and its relationship with macrophages in clinical tissue samples were in accordance with bioinformatics analysis results. SNORA5A could regulate macrophage phenotypes through TRAF3IP3 and serves as a potential prognostic marker for breast cancer patients.
- Open Access
- 29 November 2022
- Published by Springer Nature in Research Square
SNORA5A regulates tumor-associated macrophage M1/M2 phenotypes via TRAF3IP3 in breast cancer
SnoRNAs have robust potential functions and therapeutic value in breast cancer. Herein, we investigated the role SNORA5A in breast cancer. This study reviewed samples from TCGA. The transcription matrix and clinical information were analyzed using R software and validated in clinical tissue sample. SNORA5A was significantly down-regulated in breast cancer and high expression of SNORA5A correlated with a favorable prognosis. High expression of SNORA5A induced high concentration of tumor-associated macrophages M1 and low concentration of tumor-associated macrophages M2. Moreover, SNORA5A were clustered in terms related to cancer and immune functions. Possible downstream molecules of SNORA5A were identified, among which TRAF3IP3 was positively correlated with M1 and negatively correlated with M2. The function of TRAF3IP3 in tumor inhibition and its relation with macrophages in clinical tissue samples were in accordance with bioinformatics analysis results. Hence, SNORA5A could regulate macrophage phenotypes through TRAF3IP3 and serves as a potential prognostic marker for breast cancer patients.
- 29 November 2022
- Published by Springer Nature in Research Square
Open AccessSNORA5A regulates tumor-associated macrophage M1/M2 phenotypes via TRAF3IP3 in breast cancer
SnoRNAs have robust potential functions and therapeutic value in breast cancer. Herein, we investigated the role SNORA5A in breast cancer. This study reviewed samples from TCGA. The transcription matrix and clinical information were analyzed using R software and validated in clinical tissue sample. SNORA5A was significantly down-regulated in breast cancer and high expression of SNORA5A correlated with a favorable prognosis. High expression of SNORA5A induced high concentration of tumor-associated macrophages M1 and low concentration of tumor-associated macrophages M2. Moreover, SNORA5A were clustered in terms related to cancer and immune functions. Possible downstream molecules of SNORA5A were identified, among which TRAF3IP3 was positively correlated with M1 and negatively correlated with M2. The function of TRAF3IP3 in tumor inhibition and its relation with macrophages in clinical tissue samples were in accordance with bioinformatics analysis results. Hence, SNORA5A could regulate macrophage phenotypes through TRAF3IP3 and serves as a potential prognostic marker for breast cancer patients.